This thesis explores recent advancements in the treatment of ovarian cancer, highlighting both existing and emerging therapeutic strategies. It reviews the role of approved treatments like PARP inhibitors and bevacizumab, while also discussing promising new approaches such as immunotherapy, endocrine therapy, and nanoparticle-based drug delivery systems. Additionally, it investigates the potential of gene therapy to target cancer at the molecular level, focusing on overcoming drug resistance and enhancing patient outcomes. The work emphasizes the need for personalized medicine, where treatment is tailored based on the genetic profile of the cancer. Overall, the thesis underscores the importance of continued research into combining therapies to improve survival rates and reduce side effects for ovarian cancer patients.